Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

Reference:
Product nameTixagevimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade
SourceDrugBank DB16394
SpeciesHumanized
Molecular weight150kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
ApplicationsELISA,WB
Aliases /SynonymsTixagevimab,Tixagevimab,AZD8895,Covid Spike RBD,anti-Covid Spike RBD
ReferencePX-TA1032
NoteFor research use only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody

Description of Tixagevimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade

Tixagevimab is a monoclonal antibody targeting spike protein of SARS-CoV-2. This humanized biosimilar belong to the family of immunoglobulin G1- type. Tixagevimab has been recently approved by FDA and EMA to be used in emergency as prophylactic treatment against COVID-19 in association with cilgavimab.

About the Spike protein

The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.

A research grade biosimilar

Tixagevimab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Each of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic.

Publication

  • Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1, Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, Lisa Yuko Espinosa, Alex Samadi, Yuko Hiramoto, CJ Okumura, Toshiaki Maruyama, bioRxiv 2023.01.25.525589; doi: https://doi.org/10.1101/2023.01.25.525589
  • Fiedler, S., Devenish, S.R.A., Morgunov, A.S. et al. Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. Sci Rep 12, 19791 (2022). https://doi.org/10.1038/s41598-022-22214-z
  • Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

RBD Domain
Antigen

RBD Domain

PX-COV-P046 297.5$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 189$
Stable Isotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
SIL

Stable Isotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

PX-TA1032-SIL 15750$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products